Amarillo Biosciences to Reaffirm Low-Dose Interferon Research Leadership Position and Global Commitment to Support Related Therapeutics - Seite 3

About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc. (ABI) is a diversified healthcare company engaged in the discovery and development of pharmaceutical and biotech products.  Our goal is to introduce novel products that actively stimulate and rejuvenate the human body to combat disease and enhance the ability to heal.  We are an industry leader in the advancement of low-dose non-injectable interferon as a therapeutic treatment for numerous indications such as thrombocytopenia, Sjögren's syndrome, hepatitis C virus (HCV) and influenza, a potential multi-billion dollar market opportunity.  ABI primarily operates through three divisions:  Pharmaceutical, Medical and Consumer.  The Pharmaceutical division leverages a proprietary library of over a hundred scientific and clinical data studies on various human and animal applications of low-dose interferon, for patent licensing and commercialization opportunities with global partners.  The Medical division is focused on developing an innovative, state-of-the-art technology to treat metabolism related diseases such as Type 1 and Type 2 diabetes in Asia.  The Consumer division includes a range of nutraceutical and food supplement products that utilize our unique liposomal delivery systems.  ABI currently has offices in the United States and Taiwan.

FORWARD-LOOKING STATEMENTS: 

CERTAIN STATEMENTS MADE THROUGHOUT THIS DOCUMENT ARE "FORWARD-LOOKING STATEMENTS" WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 (THE "ACT"). FORWARD-LOOKING STATEMENTS INCLUDE, WITHOUT LIMITATION, ANY STATEMENT THAT MAY PREDICT, FORECAST, INDICATE OR IMPLY FUTURE RESULTS, PERFORMANCE, ACHIEVEMENTS, COSTS OR EXPENSES AND MAY CONTAIN WORDS SUCH AS "BELIEVE," "ANTICIPATE," "EXPECT," "ESTIMATE," "PROJECT," "BUDGET," “POTENTIAL,” OR WORDS OR PHRASES OF SIMILAR MEANING. FORWARD-LOOKING STATEMENTS INVOLVE RISKS AND UNCERTAINTIES THAT MAY CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE PROJECTED IN THE FORWARD-LOOKING STATEMENTS.

EXCEPT FOR THE HISTORICAL INFORMATION CONTAINED HEREIN, THE MATTERS DISCUSSED IN THIS PRESS RELEASE ARE FORWARD-LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES.  THE FOLLOWING IMPORTANT FACTORS COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENT, INCLUDING, BUT NOT LIMITED TO, THE ANTICIPATED AVAILABILITY AND POTENTIAL BENEFITS ASSOCIATED WITH THE USE OF THE PROPOSED TREATMENTS, PRODUCT QUALITY, MANUFACTURING OR SUPPLY, OR PATIENT SAFETY ISSUES,  UNCERTAINTIES RELATED TO PRODUCT DEVELOPMENT, REGULATORY AND OTHER GOVERNMENT APPROVALS UNDER INTERNATIONAL AND U.S. LAWS, THE EFFICACY OF PROPOSED TREATMENTS AND THE OUTCOME OF CLINICAL TRIALS, DEPENDENCE ON THIRD-PARTY PROPRIETARY TECHNOLOGY, INGREDIENTS, AND MATERIALS, MARKET DEMAND AND ACCEPTANCE OF ORAL INTERFERON OR THE COMPANY’S OTHER PRODUCT CANDIDATES, COMPETITIVE PRODUCTS AND TREATMENTS THAT CURRENTLY EXIST OR THAT ARE IN DEVELOPMENT, AND OTHER RISKS DETAILED FROM TIME TO TIME IN THE COMPANY’S FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION.  ABI DOES NOT UNDERTAKE TO UPDATE ITS FORWARD-LOOKING STATEMENTS.

For more information contact: [e-mail], [phone]

Attachment

• AMAR